Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MRSA
Biotech
Armata links bacteria-killing virus to responses in phase 2
The trial linked the bacteriophage to improvements in patients with infections, opening the door to work to address the limitations of antibiotics.
Nick Paul Taylor
May 19, 2025 8:41am
Basilea opts not to take MRSA antibiotic into clinic
Feb 18, 2025 4:08am
Infinity Pharma cancer drug stops COVID, MRSA damage in mice
Jul 9, 2024 7:00am
GSK drops celiac disease program acquired in Sitari buyout
Feb 1, 2023 6:40am
'Uninterpretable' phase 3 results stymie ContraFect
Dec 20, 2022 1:18pm
ContraFect halts phase 3 after antimicrobial fails futility test
Jul 14, 2022 10:35am